Srivastava, Rakesh K.


LSUHSC Stanley S. Scott Cancer Center

1700 Tulane Ave., Room 604

New Orleans, LA 70112

Ph. 504.210.2837





Ph.D., University of Guelph, Ontario, Canada


Positions and Employment

1994 - 1996.   Postdoctoral Fellow, National Cancer Institute, National INstitutes of Health, Bethesda, MD

1996 - 1999.   Fellow, National Research Council, National Academy of Sciences. Sponsored by National Institutes of Health

1999 - 2005.   Assistant Professor, Dept. of Pharmaceutical Sciences, University of Maryland, Baltimore, MD

1999 - 2005.   Associate Faculty, Greenebaum Cancer Center, University of Maryland, Baltimore, MD

1999 - 2005.   Member, Experimental Therapeutics Program, University of Maryland, Baltimore, MD

2005 - 2008.   Associate Professor, Dept. of Biochemistry Univ. of Texas Health Science Center at Tyler, TX

2008 - 2009.   Professor, Dept. of Biochemistry, Univ. of Texas Health Science Center at Tyler, TX

2009 -2014.    Tyler Endowed Professor, Dept. of Pharmacology, Toxicology and Therapeutics, and Medicine,  Univ. of Kansas Medical Center, KS

2009 - 2014.   Kansas Bioscience Authority (KBA) Eminent Scholar, Kansas City, KS

2013 - 2016    Senior Scientist, Kansas City VA Medical Center, Kansas City, MO

2015 - 2016    Professor, Department of Pharmacology, University of Missourie-Kansas City, MO

2016 -             Professor, Department of Genetics, Louisiana State University Health Sciences Center in New Orleans, LA

2016-              Professor, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA


Professional Memberships

1994 -              Member, American Association of Cancer Research

1996 -              Member, American Association for the Advancement of Science

1997 -              Member, American Society for Cell Biology

1997 -              Member, American Society for Biochemistry and Molecular Biology

2007 -              Member, American Pancreatic Association

Clinical Interests

Cancer Therapeutics

Research Interests

cell signaling, cancer cell metabolism, diabetes, nutrition, microenvironment, drug development and delivery, mouse models, stem cells, alcoholism, heavy metal toxicity, and natural products

Selected Publications

Srivastava RK, Sasaki CY, Hardwick JM, Longo DL. 1999. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription.   J Exp Med. 190: 253-65. PMCID: PMC2195578.

Srivastava RK, Mi QS, Hardwick JM, Longo DL. 1999. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis.   Proc Natl Acad Sci USA. 96: 3775-80.  PMCID: PMC22370.

Chen X, Kandasamy K, Srivastava RK . 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B (NFkB) in tumor necrosis factor-related apoptosis-inducing ligand signaling.  Cancer Res. 63:1059-66.  PMID: 12615723.

Singh TR, Shankar S, Srivastava RK . 2005. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.   Oncogene. 24:4609-23. PMID: 15897906.

Huang M, Tang S-N, Upadhyay G, Marsh JL, Jackman C, Srivastava RK, Shankar S. 2014. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras G12D mice. Cancer Lett. July 19. PMID: 25050737.

Huang M, Tang S-N, Upadhyay G, Marsh JL, Jackman, CP, Shankar S, Srivastava RK.   2014. Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from Kras G12D mice by inhibiting Akt and Sonic Hedgehog pathways.  PLoS One 9: e92161.  PMCID: PMC3973629.

Verma RK, Yu W, Shankar S, Srivastava RK. 2015. Anthothecol-encapsulated PLGA nanoparticles    inhibit pancreatic cancer cell and stem cell growth by modulating sonic hedgehog pathway. Nanomedicine: Nanotechnology, Biology and Medicine. 11:2061-70. PMID: 26199979.

 Shankar S, Nall D, Tang S-N, Meeker D, Passarini J, Sharma J, Srivastava RK.  2011. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One. 6: e16530. PMCID: PMC3031576.

Tang S-N, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK .  2012. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.   Int J Cancer. 131: 30-40. PMCID: PMC3480310.

Yu W, Ma Y, Shankar S, Srivastava RK . 2016. Role of SATB2 in human pancreatic cancer: Implications in transformation and a promising biomarker. Oncotarget. 6: 10860.  PMID: 27472393.

Yu W, Ma Y, Shankar S, Srivastava RK . 2017. SATB2/β-catenin/TCF-LEF pathway induces cellular transformation by generating cancer stem cells in colorectal cancer. Sci Rep. 7(1): 10939.  PMCID: PMC5591219.

Center of Excellence




In The News